To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

NCT02299388 on ClinicalTrials.gov · last registry update 2021-01-27

A small phase 4 — 11 participants, against a typical 75. The sponsor logged completion for November 2016. Primary outcome, as filed: Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors. liraglutide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Tulane University School of Medicine
Sponsor type: Other
Enrollment: 11
Started: 2014-10
Primary completion: 2016-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors.

Conditions studied

Diabetes Mellitus, Non-Insulin-Dependent · Hypertensive Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.